{"id":"forxiga","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":null,"aliases":["Dapagliflozin","dapagliflozin","Dapagliflozin 10 mg"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1"},"_scrapedAt":"2026-03-28T00:39:50.250Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Chronic heart failure","diseaseId":"chronic-heart-failure","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Chronic kidney disease","diseaseId":"chronic-kidney-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Diabetes mellitus type 1","diseaseId":"diabetes-mellitus-type-1","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Diabetes mellitus type 2","diseaseId":"diabetes-mellitus-type-2","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07018622","phase":"PHASE2","title":"Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity","status":"RECRUITING","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2025-05-07","conditions":"Solid Tumors, Cisplatin Nephrotoxicity","enrollment":46},{"nctId":"NCT05179668","phase":"PHASE2","title":"SGLT2 Inhibition in Hemodialysis","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2022-10-01","conditions":"Kidney Failure, Hemodialysis, Diabetes Mellitus, Type 2","enrollment":220},{"nctId":"NCT02616666","phase":"PHASE4","title":"A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2016-08-25","conditions":"Type 2 Diabetes Mellitus","enrollment":632},{"nctId":"NCT07303556","phase":"NA","title":"Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nazarbayev University","startDate":"2024-12-18","conditions":"Heart Failure, Diabete Type 2, Arterial Hypertension","enrollment":120},{"nctId":"NCT05764057","phase":"PHASE3","title":"DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-06-12","conditions":"AMI, STEMI, NSTEMI","enrollment":450},{"nctId":"NCT06560333","phase":"PHASE3","title":"iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD)","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-11-30","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT06317051","phase":"PHASE3","title":"Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kirby Institute","startDate":"2024-12-16","conditions":"HIV Infections, Weight Gain","enrollment":300},{"nctId":"NCT07269197","phase":"","title":"Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes","status":"COMPLETED","sponsor":"Josip Juraj Strossmayer University of Osijek","startDate":"2024-03-22","conditions":"Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2","enrollment":67},{"nctId":"NCT05374291","phase":"PHASE3","title":"The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD","status":"ENROLLING_BY_INVITATION","sponsor":"University Medical Center Groningen","startDate":"2022-11-08","conditions":"Kidney Disease, Chronic, Renal Transplant Failure, Heart Failure","enrollment":1750},{"nctId":"NCT07254572","phase":"PHASE4","title":"Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes","status":"RECRUITING","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2025-07-10","conditions":"Coronary Artery Disease, PreDiabetes","enrollment":300},{"nctId":"NCT07231939","phase":"","title":"Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI","status":"RECRUITING","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2025-11-01","conditions":"Coronary Artery Disease, Acute Kidney Injury, Contrast-Induced Acute Kidney Injury","enrollment":4000},{"nctId":"NCT07225465","phase":"PHASE2","title":"Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin","status":"NOT_YET_RECRUITING","sponsor":"St Vincent's Hospital Melbourne","startDate":"2026-02","conditions":"Type 1 Diabetes Mellitus","enrollment":115},{"nctId":"NCT05306210","phase":"","title":"Forxiga CKD Japan Post-Marketing Surveillance (PMS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-04-12","conditions":"Chronic Kidney Disease","enrollment":1029},{"nctId":"NCT07210307","phase":"","title":"Safety Of DAPAGLIFLOZIN (FORXIGA) in Patient With Type 2 Diabetes Mellitus (T2dm) In Vietnam From A Post-Marketing Surveillance Program","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-10-31","conditions":"Safety Outcomes","enrollment":1001},{"nctId":"NCT06072326","phase":"PHASE2","title":"dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation","status":"NOT_YET_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2026-01","conditions":"Type 1 Diabetes Mellitus With Diabetic Nephropathy","enrollment":36},{"nctId":"NCT06888505","phase":"PHASE2","title":"Dapagliflozin to Prevent Anthracycline-Induced Cardiotoxicity","status":"COMPLETED","sponsor":"Hawler Medical University","startDate":"2024-09-01","conditions":"Anthracyclines-Induced Cardiotoxicity, Cardiotoxicity","enrollment":90},{"nctId":"NCT06647745","phase":"PHASE3","title":"A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension","status":"RECRUITING","sponsor":"THPharm Corp.","startDate":"2025-04-10","conditions":"Type 2 Diabetes, Hypertension","enrollment":221},{"nctId":"NCT07143773","phase":"PHASE4","title":"SGLT2i Safety and Efficacy on Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients","status":"RECRUITING","sponsor":"Odense University Hospital","startDate":"2025-09-01","conditions":"Kidney Transplantation Recipients, Sodium-Glucose Transporter 2 Inhibitors, Non-Diabetic Patients","enrollment":88},{"nctId":"NCT07076615","phase":"PHASE4","title":"The Effect of Dapagliflozin on Patients With Cardiomyopathy","status":"RECRUITING","sponsor":"May Mohamed Abdalla","startDate":"2025-08","conditions":"Acute Decompensated Heart Failure (ADHF)","enrollment":100},{"nctId":"NCT05676684","phase":"PHASE2, PHASE3","title":"Dapagliflozin With or Without Spironolactone for HFpEF","status":"COMPLETED","sponsor":"Universidade do Porto","startDate":"2022-09-15","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":108},{"nctId":"NCT06578520","phase":"PHASE4","title":"Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure","status":"RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2024-07-30","conditions":"Heart Failure","enrollment":31},{"nctId":"NCT07096986","phase":"PHASE2","title":"Impact of Dapagliflozin for the Regulation of Immunological Activity in Membranous Nephropathy","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2025-11-01","conditions":"Glomerulonephritis","enrollment":20},{"nctId":"NCT06054035","phase":"PHASE4","title":"SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2023-10-26","conditions":"Type2diabetes, PreDiabetes, Renal Failure","enrollment":170},{"nctId":"NCT02879409","phase":"NA","title":"HbA1c Variability in Type II Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Cornell Medical College in Qatar","startDate":"2016-11","conditions":"Diabetes Mellitus Type 2","enrollment":150},{"nctId":"NCT04735042","phase":"","title":"SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.","status":"COMPLETED","sponsor":"University of Pisa","startDate":"2020-10-07","conditions":"Type 2 Diabetes, Urinary Tract Infections","enrollment":60},{"nctId":"NCT04451837","phase":"PHASE2","title":"Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology","status":"ACTIVE_NOT_RECRUITING","sponsor":"Region Skane","startDate":"2020-09-10","conditions":"Type2 Diabetes","enrollment":200},{"nctId":"NCT04865406","phase":"","title":"Forxiga HF General Drug Use-Results Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-05-10","conditions":"Heart Failure","enrollment":1221},{"nctId":"NCT06845163","phase":"PHASE2","title":"Randomized Clinical Trial to Evaluate the Effect of Dapagliflozin in Patients With Diabetic Macular Edema","status":"RECRUITING","sponsor":"Alexandria University","startDate":"2025-02-08","conditions":"Diabetic Macular Edema, Center-involved Diabetic Macular Edema","enrollment":56},{"nctId":"NCT06668389","phase":"PHASE4","title":"Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2025-05-12","conditions":"Congenital Heart Disease, Repaired Tetralogy of Fallot (rTOF), Pulmonary Regurgitation","enrollment":106},{"nctId":"NCT05884866","phase":"PHASE2","title":"A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease.","status":"RECRUITING","sponsor":"Klinikum Nürnberg","startDate":"2023-07-13","conditions":"Chronic Renal Failure, Mechanistic Effects of SGLT2 Inhibition and/ or MR Antagonism on Body Fluid and Electrolyte Homeostatis, Chronic Kidney Disease Stage 3","enrollment":100},{"nctId":"NCT06271200","phase":"NA","title":"Strategic Lifestyle Intervention for Metabolic Syndrome (SLIM-MET)","status":"RECRUITING","sponsor":"National Health Research Institutes, Taiwan","startDate":"2024-03-14","conditions":"Metabolic Syndrome","enrollment":200},{"nctId":"NCT05852704","phase":"PHASE3","title":"SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF","status":"RECRUITING","sponsor":"Region Örebro County","startDate":"2024-04-04","conditions":"Chronic Coronary Syndrome, Atrial Fibrillation","enrollment":800},{"nctId":"NCT05250011","phase":"","title":"Observation of Italian Patients With Heart Failure Being Treated With Dapagliflozin in Clinical Practice","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-04-19","conditions":"Heart Failure, Reduced Ejection Fraction","enrollment":252},{"nctId":"NCT06000462","phase":"PHASE4","title":"The Effect of Dapagliflozin on Weight Loss in Obese Adults Without Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oman Ministry of Health","startDate":"2024-04-22","conditions":"Obesity, Dapagliflozin Adverse Reaction, Weight Loss","enrollment":150},{"nctId":"NCT05743907","phase":"PHASE4","title":"Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2023-04-25","conditions":"Diabetes Mellitus","enrollment":231},{"nctId":"NCT04564742","phase":"PHASE3","title":"Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-12-22","conditions":"Acute Myocardial Infarction, Heart Failure","enrollment":4017},{"nctId":"NCT05782972","phase":"PHASE4","title":"Therapeutic Response of Sodium-glucose Co-transporter Type-2 Inhibitor in Non-diabetic MAFLD Patients: a Pilot Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","startDate":"2023-03-11","conditions":"Metabolic Associated Fatty Liver Disease","enrollment":50},{"nctId":"NCT06615674","phase":"PHASE4","title":"Effect of Dapagliflozin Administration on the Apoptosis Levels of Patients With Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Yoga Yudhistira","startDate":"2024-09-21","conditions":"Acute Myocardial Infarction (AMI), STEMI - ST Elevation Myocardial Infarction (MI), NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)","enrollment":40},{"nctId":"NCT06821919","phase":"","title":"Impact of Antiglycemic & Immunosuppressive Therapies on NETosis in Diabetes & Kidney Disease (NETs - Neutrophil Traps)","status":"RECRUITING","sponsor":"Western Galilee Hospital-Nahariya","startDate":"2024-05-13","conditions":"Diabetes Mellitus, Kidney Disease","enrollment":70},{"nctId":"NCT06065280","phase":"NA","title":"Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2022-11-01","conditions":"Heart Failure, Reduced Ejection Fraction Heart Failure","enrollment":80},{"nctId":"NCT06420167","phase":"PHASE2","title":"DapagliFLOzin in Renal AL Amyloidosis (FLORAL)","status":"RECRUITING","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2024-07-11","conditions":"Renal AL Amyloidosis","enrollment":20},{"nctId":"NCT06155604","phase":"PHASE2","title":"SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2023-01-04","conditions":"Lupus Nephritis, Chronic Kidney Diseases","enrollment":150},{"nctId":"NCT04234867","phase":"PHASE1","title":"Study to Explore the Effect of Dapagliflozin and Stress in Adolescent and Adult Subjects With Type 1 Diabetes (T1D)","status":"TERMINATED","sponsor":"Kinderkrankenhaus auf der Bult","startDate":"2022-05-18","conditions":"Type 1 Diabetes, Diabetic Ketoacidosis","enrollment":2},{"nctId":"NCT06304857","phase":"PHASE3","title":"CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL","status":"RECRUITING","sponsor":"4th Military Clinical Hospital with Polyclinic, Poland","startDate":"2024-04-15","conditions":"Breast Cancer, Heart Failure","enrollment":188},{"nctId":"NCT05424315","phase":"PHASE2, PHASE3","title":"Impact of DApagliflozin on Cardiac Function Following Anterior Myocardial Infarction in Non-Diabetic Patients","status":"COMPLETED","sponsor":"Omar Younis","startDate":"2021-10-01","conditions":"Anterior MI","enrollment":100},{"nctId":"NCT06690723","phase":"PHASE3","title":"Vitamin D and SGLT-2 Inhibitor in CPAP-naive Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"University Malaysia Sarawak","startDate":"2022-06-08","conditions":"Obstructive Sleep Apnea","enrollment":160},{"nctId":"NCT04869124","phase":"PHASE4","title":"Dapagliflozin on Volume Vascular Outcomes.","status":"COMPLETED","sponsor":"Frank Ruschitzka","startDate":"2021-02-15","conditions":"Heart Failure，Congestive","enrollment":80},{"nctId":"NCT06612086","phase":"PHASE1","title":"Dapagliflozin in Mangement of Pulmonary Hypertension Patients","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-10-25","conditions":"Pulmonary Hypertension","enrollment":70},{"nctId":"NCT06576375","phase":"PHASE3","title":"Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome","status":"RECRUITING","sponsor":"Future University in Egypt","startDate":"2024-09-02","conditions":"Polycystic Ovary Syndrome","enrollment":70},{"nctId":"NCT05849766","phase":"PHASE3","title":"Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle Dysfunction","status":"COMPLETED","sponsor":"October 6 University","startDate":"2023-04-27","conditions":"Dilated Cardiomyopathy","enrollment":150},{"nctId":"NCT02987738","phase":"PHASE1","title":"Pilot Study to Explore the Efficacy of DAPAglifozin as add-on to Closed-loop Control in Patients With Type 1 Diabetes","status":"COMPLETED","sponsor":"Kinderkrankenhaus auf der Bult","startDate":"2017-02-09","conditions":"Type1diabetes","enrollment":30},{"nctId":"NCT06535529","phase":"PHASE3","title":"Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients","status":"RECRUITING","sponsor":"Helwan University","startDate":"2024-08-24","conditions":"Acute Decompensated Heart Failure","enrollment":60},{"nctId":"NCT04004793","phase":"PHASE4","title":"Remission of Type 2 Diabetes With Dapagliflozin (READ Trial)","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-06-12","conditions":"Type 2 Diabetes","enrollment":328},{"nctId":"NCT04707261","phase":"PHASE4","title":"Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)","status":"RECRUITING","sponsor":"Xiangtan Central Hospital","startDate":"2021-08-06","conditions":"Anemia, Heart Failure","enrollment":1990},{"nctId":"NCT03199053","phase":"PHASE3","title":"Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-10-11","conditions":"Diabetes Mellitus, Type 2","enrollment":256},{"nctId":"NCT06434025","phase":"PHASE3","title":"IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency","status":"NOT_YET_RECRUITING","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2024-05-24","conditions":"Heart Failure, Systolic, Iron Deficiencies","enrollment":99},{"nctId":"NCT06417320","phase":"PHASE4","title":"Effect of Sodium-glucose Cotransporter-2 Inhibitors (SGLT-2i) on Proteinuria in Nephrotic Children Older Than 10 Years","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2023-06-01","conditions":"Nephrotic Syndrome in Children","enrollment":60},{"nctId":"NCT06405178","phase":"PHASE3","title":"Adjuvant Therapy With Letrozole in Induction of Ovulation With Polycystic Ovarian Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Beni-Suef University","startDate":"2024-09-30","conditions":"Polycystic Ovary","enrollment":500},{"nctId":"NCT05392959","phase":"PHASE4","title":"Effect of the Antidiabetic Drug Dapagliflozin on the Coronary Macrovascular and Microvascular Function in Type 2 Diabetic Patients","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire Saint Pierre","startDate":"2022-06-06","conditions":"Diabetes Mellitus, Type 2","enrollment":4},{"nctId":"NCT06374043","phase":"PHASE4","title":"Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2021-05-11","conditions":"Diabetes Mellitus, Type 2, Diabetes Mellitus Type 2 With Proteinuria, Diabetes Mellitus","enrollment":20},{"nctId":"NCT06344247","phase":"NA","title":"Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2023-09-01","conditions":"Obesity, Chronic Kidney Diseases","enrollment":48},{"nctId":"NCT06341842","phase":"PHASE2","title":"Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced Cardiotoxicity","status":"RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2023-10-19","conditions":"Breast Cancer","enrollment":316},{"nctId":"NCT06201000","phase":"","title":"Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients","status":"UNKNOWN","sponsor":"October 6 University","startDate":"2023-12-27","conditions":"Genetic Polymorphisms, Heart Failure","enrollment":282},{"nctId":"NCT05017987","phase":"PHASE1","title":"Clinical Trial to Compare Pharmacokinetics After Administration of ATB-101 or Co-administration of ATB-1011 and ATB-1012","status":"COMPLETED","sponsor":"Autotelicbio","startDate":"2021-06-19","conditions":"Healthy Adult Volunteers","enrollment":36},{"nctId":"NCT06233045","phase":"PHASE1","title":"Dapagliflozin Tablet 10 mg Relative to Forxiga® Tablets 10 mg","status":"UNKNOWN","sponsor":"Bio-innova Co., Ltd","startDate":"2024-07-23","conditions":"Healthy Subjects","enrollment":30},{"nctId":"NCT03782259","phase":"PHASE4","title":"Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2","status":"COMPLETED","sponsor":"University of Washington","startDate":"2019-02-26","conditions":"Type 2 Diabetes Mellitus, Myocardial Fibrosis, Myocardial Inflammation","enrollment":62},{"nctId":"NCT06111443","phase":"PHASE2, PHASE3","title":"Effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2023-12-01","conditions":"Atrial Fibrillation Recurrent, Catheter Ablation","enrollment":196},{"nctId":"NCT06128096","phase":"","title":"The Effect of SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac Function in T2DM Patients With CAD (EpiCAD)","status":"UNKNOWN","sponsor":"Clinical Research Centre, Malaysia","startDate":"2022-06-01","conditions":"Coronary Artery Disease","enrollment":360},{"nctId":"NCT06063109","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Safety and the Pharmacokinetic Interaction of Telmisartan and Dapagliflozin.","status":"COMPLETED","sponsor":"THPharm Corp.","startDate":"2023-10-09","conditions":"Hypertension, Diabetes Mellitus, Type 2","enrollment":51},{"nctId":"NCT04333823","phase":"PHASE3","title":"Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial","status":"UNKNOWN","sponsor":"The Hospital for Sick Children","startDate":"2020-12-11","conditions":"Diabetes Mellitus, Type 1","enrollment":100},{"nctId":"NCT06127212","phase":"NA","title":"Bioequivalence Study of Dapagliflozin 10 mg Film-coated Tablets","status":"COMPLETED","sponsor":"Dexa Medica Group","startDate":"2023-03-08","conditions":"Healthy","enrollment":24},{"nctId":"NCT04049110","phase":"PHASE3","title":"Dapagliflozin in Physical Exercise in Type 1 Diabetes","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2020-08-25","conditions":"Diabetes Mellitus, Type 1","enrollment":39},{"nctId":"NCT05998525","phase":"PHASE3","title":"Dapagliflozin Effects on Coronary Calcium and Epicardial Fat Assessed by Cardiotomography","status":"COMPLETED","sponsor":"Hilda Elizabeth Macías Cervantes","startDate":"2021-06-21","conditions":"Diabete Type 2, Unstable Angina, Myocardial Infarction","enrollment":54},{"nctId":"NCT05915949","phase":"PHASE4","title":"Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and Safety","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2022-01-01","conditions":"Diabetes Type 2","enrollment":99},{"nctId":"NCT04393246","phase":"PHASE2, PHASE3","title":"mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2020-07-03","conditions":"COVID-19","enrollment":454},{"nctId":"NCT03619213","phase":"PHASE3","title":"Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-08-27","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":6263},{"nctId":"NCT03710460","phase":"PHASE4","title":"Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in Obesity","status":"UNKNOWN","sponsor":"University of Guadalajara","startDate":"2019-07-30","conditions":"Obesity","enrollment":33},{"nctId":"NCT05848102","phase":"PHASE4","title":"Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Fibrosis (DEFORM)","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-12-23","conditions":"Functional Mitral Regurgitation","enrollment":166},{"nctId":"NCT04080518","phase":"PHASE4","title":"Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment","status":"COMPLETED","sponsor":"National Heart Centre Singapore","startDate":"2019-11-11","conditions":"Diabetes Mellitus, Heart Failure","enrollment":40},{"nctId":"NCT05776043","phase":"PHASE3","title":"Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure","status":"UNKNOWN","sponsor":"Medical University of Warsaw","startDate":"2022-03-15","conditions":"Acute Decompensated Heart Failure","enrollment":1364},{"nctId":"NCT04035031","phase":"PHASE3","title":"Effects of Dapagliflozin on Hormonal Glucose Homeostasis in Type 1 Diabetes","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2020-01-09","conditions":"Diabetes Mellitus, Type 1","enrollment":13},{"nctId":"NCT05710367","phase":"PHASE2","title":"Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients","status":"UNKNOWN","sponsor":"Albina Nowak, MD","startDate":"2023-08","conditions":"Fabry Disease","enrollment":46},{"nctId":"NCT05686616","phase":"NA","title":"SGLT2 Inhibitor for Severe Tricuspid Regurgitation","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2022-04-13","conditions":"Tricuspid Regurgitation","enrollment":72},{"nctId":"NCT05420285","phase":"PHASE2","title":"Cardiometabolic Effects of Dapagliflozin in Heart Failure With Reduced or Mildly Reduced Ejection Fraction","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-06-26","conditions":"Heart Failure, Reduced Ejection Fraction","enrollment":40},{"nctId":"NCT04778787","phase":"PHASE4","title":"Sodium-glucose Cotransporter Type 2 Inhibitors for Acute Cardiorenal Syndrome Prevention","status":"COMPLETED","sponsor":"I.M. Sechenov First Moscow State Medical University","startDate":"2021-01-01","conditions":"Congestive Heart Failure","enrollment":370},{"nctId":"NCT03714594","phase":"PHASE2","title":"Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.","status":"COMPLETED","sponsor":"University of Pisa","startDate":"2018-07-24","conditions":"Type2 Diabetes Mellitus","enrollment":48},{"nctId":"NCT04923295","phase":"NA","title":"The Effect of Dapagliflozin on Ultrafiltration Among Peritoneal Dialysis Patients","status":"COMPLETED","sponsor":"An-Najah National University","startDate":"2021-06-02","conditions":"Peritoneal Dialysis Complication, Ultrafiltration Failure","enrollment":20},{"nctId":"NCT05565976","phase":"PHASE2, PHASE3","title":"Dapagliflozin Effect in Cognitive Impairment in Stroke Trial","status":"UNKNOWN","sponsor":"Jaime Daniel Mondragon","startDate":"2020-08-01","conditions":"Stroke, Ischemic, Mild Cognitive Impairment, Dementia, Vascular","enrollment":270},{"nctId":"NCT05477017","phase":"","title":"Evaluation of SGLT2-i Effectivness and Safety in Elderly Type 2 Diabetes Patients","status":"UNKNOWN","sponsor":"University of Milan","startDate":"2022-09","conditions":"Type2Diabetes","enrollment":800},{"nctId":"NCT03766750","phase":"PHASE3","title":"Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus.","status":"WITHDRAWN","sponsor":"EMS","startDate":"2021-12","conditions":"Type2 Diabetes Mellitus","enrollment":""},{"nctId":"NCT05266404","phase":"PHASE1","title":"Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-03-21","conditions":"Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)","enrollment":46},{"nctId":"NCT05418946","phase":"","title":"The Effects of Dapagliflozin in Normal Clinical Practice in T2D","status":"UNKNOWN","sponsor":"University of Milan","startDate":"2022-06","conditions":"Type 2 Diabetes","enrollment":1400},{"nctId":"NCT03537131","phase":"PHASE2","title":"Dapagliflozin During Exercise for the PrevenTion of Hypoglycaemia","status":"TERMINATED","sponsor":"University of Oxford","startDate":"2018-06-02","conditions":"Diabetes Mellitus, Type 1","enrollment":9},{"nctId":"NCT04856007","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of Fixed Dose Combination of Dapagliflozin/Metformin XR Relative to Co-administration of the Individual Components in Healthy Chinese Subjects.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-04-12","conditions":"Healthy Volunteer","enrollment":80},{"nctId":"NCT04356742","phase":"PHASE3","title":"Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2020-05-26","conditions":"Type 2 Diabetes","enrollment":198},{"nctId":"NCT02725593","phase":"PHASE3","title":"Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-22","conditions":"Type 2 Diabetes","enrollment":72},{"nctId":"NCT05217654","phase":"PHASE1","title":"Trial to Investigate the Effect of Dapagliflozin on Ischemia Reperfusion Induced Endothelial Dysfunction","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2022-02-18","conditions":"Reperfusion Injury, Vascular Complications","enrollment":32},{"nctId":"NCT02338921","phase":"PHASE4","title":"Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2015-01","conditions":"Type 2 Diabetes","enrollment":78},{"nctId":"NCT03423355","phase":"PHASE4","title":"Dapagliflozin Effect on Erythropoiesis and Physical Fitness","status":"WITHDRAWN","sponsor":"University Hospital Tuebingen","startDate":"2021-09","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":""},{"nctId":"NCT04170998","phase":"PHASE3","title":"Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2020-01-02","conditions":"Type2 Diabetes","enrollment":283}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":38,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Forxiga","genericName":"Forxiga","companyName":"AstraZeneca Turkey","companyId":"astrazeneca-turkey","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":59,"withResults":3},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}